FISCAL YEAR 2017 ANNUAL REPORT

FISCAL YEAR 2017 ANNUAL REPORT

The Bottom Line 2 Tax Incentive Fund and Business Development 4 2017 Tax Incentive Program 5 Notable FY 17 Arrivals & Expansions 7 Capital Fund Update & Workforce Development 9 The Internship Challenge 10 Investing in Infrastructure 11 2017 STEM Equipment & Supply Grant Awardees 13 TABLE OF CONTENTS Investment Fund Update & The Way Forward 15 Funding the Companies of Tomorrow 17 Staying Connected 18 Financial Summary 20 The Way Forward 21

IF YOU WANT IT TO HAPPEN, YOU NEED TO BE HERE This is our ethos as we move into the next generation of the Massachusetts Life Sciences Center with the support of academic institutions, companies, associations, municipalities, and the administration. With this as one of our guiding principles, we continue to work towards maintaining the Commonwealth s position as a beacon for the advancement of human health. This ecosystem is supported by a foundation unlike any other industry. The infrastructure (lab space, equipment, supplies, etc.) required for the advancement we have seen in the life sciences cannot be compared with what s needed for the advancement you might find in construction or finance. It is crucial that our investments continue to support this innovation infrastructure, as it is some of the hardest money to come by for researchers and manufacturers. In that same vein, the workforce in Massachusetts, while being the most educated in the nation, requires an incubation period longer than any other field. We invest in students, educators, and employers to continue producing the most advanced life sciences workforce in the nation. To that end, this year has been very exciting for the Center and for the State. We ran a full slate of programs aimed at supporting the innovation infrastructure, talent development, and sustaining the entrepreneurial growth that takes place in this ecosystem. Through these programs, we ve invested more than $77 million last fiscal year. In addition, we have received Accelerator Loan repayments from four companies, our highest repayment total in a fiscal year yet. Going forward in the future, as you may have heard, Governor Baker has led the charge filing a bill recommending support of $500M over five years for the MLSC. Continued support from the State Legislature, as well as our partners in academia and industry has been integral in demonstrating that no one entity is responsible for the healthy state of this industry. I speak for everyone at the Center when I say we are looking forward to continuing to play our part in the important scientific and economic work being done in Massachusetts. Travis McCready President & CEO, Massachusetts Life Sciences Center 1

THE BOTTOM LINE As of June 30, 2017, the MLSC managed a portfolio of more than 630 grants and loans. Since its creation, the agency has invested or committed more than $655 million, which has generated more than $2.8 billion in additional investment in the Commonwealth. This has created a portfolio of more than $3.4 billion in publicprivate investments in the state s life sciences ecosystem. Project/Award Count $ Amount Capital Projects 80 $429,758,376 Company Grants and Loans 82 $34,655,508 Academic Research 52 $27,256,555 Tax Incentives 126 $116,673,777 Internships 3100+ $18,358,822 Equipment and Supplies 191 $17,472,246 Other Grants 106 $11,810,065 Total: 3737 $655,985,349 FY17 INVESTMENT HIGHLIGHTS Tax incentive awards totaling more than $19 million to 22 companies that committed to create more than 1,250 new jobs by the end of the 2017 calendar year. More than 60% of awardees are located outside of Boston and Cambridge More than 500 interns placed this fiscal year, more than any prior year. This year also saw the placement of the 3,000th internship since the program s inception $39 million in Capital and STEM Equipment Grant funding to educational and research institutions across the state More than $1.5 million awarded to support early-stage company development through the Massachusetts Ramp Up Program 2 Four previous Accelerator Loan recipients repaid their loans including interest

GOVERNOR BAKER S $500M COMMITMENT Governor Charlie Baker joined the MLSC and MassBio at the BIO International Convention in San Diego to reaffirm his administration s commitment to the life sciences in the Commonwealth as well as help build the excitement of BIO taking place in Boston in 2018. Prior to arriving in San Diego, the Governor announced a proposal to continue funding the Life Sciences Initiative for five years and $500 million. The proposal includes up to $295 million in capital authorization and up to $150 million job-creating tax incentives. The funding will continue to be managed by the MLSC. 3

TAX INCENTIVE FUND & BUSINESS DEVELOPMENT

2017 TAX INCENTIVE PROGRAM The Life Sciences Initiative authorizes up to $25 million in tax incentives each year for companies engaged in life sciences research and development, commercialization, and manufacturing. A total of 39 companies applied for tax incentives over the past year, and the MLSC awarded over $19 million to 22 companies (see below). The companies receiving tax incentive awards committed to the creation of 1,276 new jobs in the Commonwealth. Company Location Abiomed Inc. Danvers Alkermes, Inc. Waltham Anika Therapeutics, Inc. Bedford Berkshire Sterile Manufacturing, Inc. Lee Commonwealth Diagnostics International, Inc. Salem EMD Holding Corporation Billerica Ginkgo Bioworks, Inc. Boston Kala Pharmaceuticals, Inc. Waltham RADIUS HEALTH INC Waltham Shire Human Genetic Therapies, Inc. Lexington TESARO, Inc. Waltham Amount Awarded Jobs $750,000 50 $1,500,000 100 $225,000 15 $370,000 25 $330,000 22 $1,200,000 80 $300,000 20 $150,000 10 $150,000 10 $3,000,000 200 $1,800,000 120 Company Location Acorda Therapeutics, Inc. Waltham Alnylam Pharmaceuticals, Inc. Cambridge Astellas Institute for Regenerative Medicine Marlborough Blueprint Medicines Corporation Cambridge Confer Health, Inc. Charlestown Fulcrum Therapeutics, Inc. Cambridge Insulet Corporation Billerica ProTom International Holding Corporation Wakefield Sage Therapeutics Inc. Cambridge Siemens Healthcare Diagnostics Inc. East Walpole WAVE Life Sciences USA, Inc. Cambridge Amount Awarded Jobs $495,000 33 $1,875,000 125 $750,000 50 $525,000 35 $150,000 10 $270,000 18 $1,650,000 110 $150,000 10 $1,500,000 100 $2,058,000 84 $735,000 49 In May, the MLSC celebrated with Tax Incentive awardee Anika Therapeutics for its 25th anniversary. The celebration also served as a ribbon cutting for the new 134,000 sq.ft. consolidated global manufacturing facility at the company s headquarters in Bedford. The facility will house a portion of the new 15 employees committed through its Tax Incentive award. 5

SUMMARY OF TAX INCENTIVE PROGRAM FROM INCEPTION TO JUNE 30, 2017 To date, 207 awards have been authorized under this program representing $181 million of incentives in creating over 8,800 net new jobs across the Commonwealth and maintaining them over a 5 year period. As part of the MLSC s agreements with awardees, recipients of tax incentives are required to report job creation results to the Center by the end of the calendar year. Under the Life Sciences Act, the Department of Revenue has the authority to recover or claw back incentives from companies that the MLSC determines will not meet the minimum job creation threshold in their tax incentive agreement. There are 85 active awards from the 2012 through 2016 program years, with a combined commitment of 4,209 net new jobs under the program. AS OF JUNE 30, 2017 Collectively, awardees from the 2009, 2010 and 2011 programs completed their 5 year term on December 31, 2014, 2015 and 2016 respectively. The awardees from the 2012 program will complete their 5 year term on December 31, 2017. The results of these awards will be reported to the MLSC in January 2018. The completed awards have created, hired and maintained 1,507 net new jobs over a period of 5 years under the program. 6 17 awardees have declined their awards due to changes in their business or general economic conditions. 64 awardees voluntarily terminated their agreements, either by foregoing taking the tax benefits, or by returning the benefits to the Commonwealth if they had already received them. Since inception, the MLSC has decertified two awardees for not achieving the statutory thresholds.

NOTABLE FY17 ARRIVALS & EXPANSIONS In 2017, Billerica-based Insulet Corporation broke ground on its new 300,000+ sq.ft. facility in Acton. The space will be home to the company s only manufacturing plant in the U.S. and potentially, headquarters for the 640 person company. This purchase continues the growth the insulin pump device company has seen since its founding in 2000, after moving to a 195,000 sq.ft. space in Billerica from Bedford in 2014, and posting $367 million in revenue in 2016. Qilu Pharmaceutical is one of the 10 largest pharmaceutical companies in China with more than $2 billion in sales annually. The Chinese drugmaker recently arrived in Massachusetts by purchasing a two-story office building in Brighton. A 16-person Qilu subsidiary will work on the second floor while the first floor of the 25,000 sq.ft. space is expected to be an incubator space for other local startups and entrepreneurs. Boston Mayor Marty Walsh helped celebrate the company s arrival in May. Grunenthal, founded in 1946, is a family-owned drug development company with more than 5,000 employees worldwide and $1.5 billion in annual revenue. In May 2017, the company announced its arrival to Massachusetts with lab space opening in the Cambridge Innovation Center. Grunenthal s CEO has expressed the possibility of consilidation of its U.S. operations (20 additional employees) to the Cambridge location in the future. LEO PHARMA Her Royal Highness, Crown Princess Mary of Denmark joined life sciences leadership in Cambridge in September 2016 to open the LEO Science & Tech Hub. The Hub aims to catalyze earlystage collaborations in science and technology in order to advance the treatment of skin diseases and is the first of its kind to focus on dermatology in the Greater Boston area. Since opening, the LEO Science & Tech Hub has entered into a partnerhsip with MLSC funded Karp Lab at Brigham and Women s Hospital as well as investing in Boston based Novopyxis. 7

8 In September, the MLSC was proud to take part in the ribbon cutting officially opening Thermo Fisher Scientific s newly constructed global headquarters at 168 Third Avenue in Waltham. The 286,000 sq.ft. headquarters is home to 330 employees and was opened in conjunction with the 10th anniversary of Thermo Fisher s founding.

CAPITAL FUND UPDATE & WORKFORCE DEVELOPMENT

THE INTERNSHIP CHALLENGE The Internship Challenge has continued to be the MLSC s flagship workforce development program. The year-round program is designed to expand the pool of prospective employees who have practical experience, enhance opportunities for mentoring, enable more students to explore career opportunities, and expose students to entrepreneurship. In FY17, the Internship Challenge Program surpassed a major milestone by funding its 3,000th internship. LEXINGTON MEDICAL Lexington Medical, Inc. is a new medical device company developing patentpending abdominal surgical instruments. The company celebrated the opening of their new 8,000 square foot headquarters in Billerica in December. The new facility will house the company s current 10 employees including Harvard MBA candidate Surabhi Bhandari who began her time with Lexington Medical as an intern who participated in the MLSC s Internship Challenge program. At the conclusion of her internship with the company, Surabhi was hired as a full time employee. She is among the more than 400 interns who are hired full time by their host company at the conclusion of their internship. To date, the program has created more than 3,150 paid internship opportunities at over 650 life sciences companies throughout the Commonwealth. Interns have represented nearly 200 different colleges and universities. More than 3,150 Interns Placed Since Beginning of Program 46% Women 22% Hired Post Internship (Part- and Full-Time) 84% in STEM Major 10

INVESTING IN INFRASTRUCTURE The MLSC uses its Capital Fund to strategically invest in innovation infrastructure, design programs to train the next generation of the most educated life sciences workforce in the country, and to create and improve working spaces for early stage companies. To date, MLSC infrastructure investments have contributed or will contribute to the creation of more than 1.8 million square feet of new life sciences research and manufacturing space across the Commonwealth, while creating more than 5,200 jobs in the building trades and in the life sciences. In FY17, more than $39 million in capital funding was awarded to 63 research centers and life sciences training facilities (listed below and on following pages) at colleges, universities, middle schools and high schools across Massachusetts. 10 previously funded projects were completed during the year, bringing completed projects to 44 representing $235 million in MLSC investment. BioBuilder Learning Lab, Cambridge $500,000 Dana-Farber Cancer Institute, Boston $4,629,019 Framingham State University, Framingham $454,000 Harvard Medical School, Boston $4,345,000 Institute for Protein Innovation, Boston $5,000,000 Mount Wachusett Community College, Gardner $1,646,787 UMass Lowell, Lowell $5,000,000 Bristol Community College, Fall River $4,400,000 Dean College, Franklin $297,030 Gloucester Marine Genomics Institute $2,744,219 Harvard T. H. Chan School of Public Health, Boston $4,912,307 Merrimack College, Andover $500,000 Smith College, Northampton $496,638 Westfield State University, Westfield $75,000 GLOUCESTER MARINE GENOMICS INSTITUTE The Gloucester Marine Genomics Institute will establish a world-class marine genomics research institute on Gloucester Harbor, integrating the dynamic components of scientific discovery, workforce development and investment, and diversifying Gloucester s maritime economy. 11

The MLSC announced the more than $39 million in Capital Infrastructure and STEM Equipment & Supply grants across the state. In February, a regional awards ceremony was held at Bristol Community College in Fall River. 12

2017 STEM EQUIPMENT & SUPPLY GRANT AWARDEES Metro Boston Boston Educational Development Foundation, Inc., Boston - $222,415 Brooke Charter High School, Boston - $100,000 Cambridge Rindge and Latin School, Cambridge - $105,000 Chelsea High School, Chelsea - $108,029 East Boston High School, Boston - $110,000 George Keverian Middle School, Everett - $59,629 Jeremiah E. Burke High School, Boston - $105,700 John D. O'Bryant School of Mathematics and Science, Boston - $186,420 Lynn English High School, Lynn - $57,311 Madison Park Technical Vocational High School, Boston - $110,000 Malden High School, Malden - $26,000 Massachusetts Biotechnology Education Foundation, Cambridge - $95,000 Medford Vocational Technical High School, Medford - $99,516 O Maley Innovation Middle School, Gloucester - $56,933 Prospect Hill Academy Charter School, Cambridge - $21,000 Snowden International School, Boston - $101,600 TechBoston Academy High School, Boston - $105,970 Southeast Bristol-Plymouth Regional Technical High School, Taunton - $100,000 Brockton High School, Brockton - $109,988 Diman Regional Vocational Technical High School, Fall River - $99,951 Global Learning Charter Public School - New Bedford $107,982 Gloucester High School, Gloucester - $109,154 New Bedford High School, New Bedford - $110,000 New Bedford Middle Schools, New Bedford - $25,000 Matthew J. Kuss Middle School, Fall River - $40,530 Quincy Middle Schools, Quincy - $121,890 Southeastern Regional Vocational Technical High School, North Easton - $99,995 Northeast Collins Middle School, Salem - $39,525 Greater Lawrence Technical High School, Andover - $93,410 Minuteman Regional Vocational Technical High School, Lexington - $108,172 Nashoba Valley Technical High School, Westford - $101,476 Richardson Middle School, Dracut - $60,000 Shawsheen Valley Technical High School, Billerica - $110,000 Tenney Grammar School, Methuen - $49,678 Whittier Regional Vocational Technical High School, Haverhill - $109,342 Western Baystate Academy Charter Public School, Springfield - $110,000 Chicopee Comprehensive High School, Chicopee - $105,579 Holyoke High School and Dean Technical High School, Holyoke - $210,798 McCann Technical School, North Adams - $29,164 Springfield High School of Commerce, Springfield - $110,000 Springfield Renaissance School, Springfield - $40,040 Veritas Preparatory Charter School, Springfield - $38,000 Central Bartlett High School, Webster - $16,112 Goodrich Academy, Fitchburg - $105,345 Montachusett Regional Vocational Technical School, Fitchburg - $99,697 Northbridge High School, Whitinsville - $110,000 Quaboag Middle Innovation School, Warren - $50,000 Sizer Charter School, Fitchburg - $14,780 South High Community School, Worcester - $91,609 13

HIGH SCHOOL APPRENTICESHIP CHALLENGE In May, the MLSC and the BioBuilder Educational Foundation (BioBuilder) held graduation ceremonies for the High School Apprenticeship Challenge Lab Training Program at Worcester Technical High School and LabCentral in Cambridge. Forty-three students from Greater Boston and Worcester-area public schools successfully completed an eight-week lab training program designed to prepare them for summer internships. The training was funded through a $400,000 investment by the MLSC, which will also subsidize around 100 paid internship opportunities. The program, hosted for the second year by the MIT Department of Biological Engineering, was expanded this year to also serve students from the Worcester public schools. The Worcester-area training was hosted by Worcester Technical High School. 14

INVESTMENT FUND UPDATE & THE WAY FORWARD

16 ACCELERATOR REPAYMENTS IN FY2017 Through the MLSC s Accelerator Loan Program, 32 early stage life sciences companies have been awarded loans to advance a company s product commercialization. Four previous Accelerator loan Awardees repaid their loans in FY17. The companies, their loan amount from the MLSC and repayment amount are below. Company Amount Awarded Amount Repaid Allurion $750,000 $1,115,824.71 Arch Therapeutics $1,000,000 $1,361,268.28 ImmuneXcite $984,500 $1,332,627.83 WolfeLabs $500,000 $920,270.08

FUNDING THE COMPANIES OF TOMORROW The MLSC announced more than $1.6 million in awards to eight life sciences companies through the first-round of the Massachusetts Ramp-Up Program (MassRamp). MassRamp provides grant funding to promising early-stage life sciences companies. The awards are designed to help bridge the funding gaps associated with the long life sciences R&D cycle, and the high cost of translating research into commercially viable products. Company Location Product Descripton Aldatu Biosciences DS Labs (dba Kohana) HydroGlyde Coatings, LLC Lariat Biosciences, Inc. Micro-Leads Inc. Platelet Biogenesis Cambridge Canton Brookline Beverly Boston Boston REBIScan, Inc. Cambridge Snapdragon Chemistry Cambridge Reagent development and testing for treatment-resistant minority variants of HIV Complete final steps towards commercialization for breast pump platform technology via quality system development and e-commerce launch Translation of HydroGlyde Coated Condoms towards FDA approval and commercialization Liquid Biopsy for Comprehensive Genetic Profiling in cancer patients Clinical feasibility study to determine efficacy of stimulation electrodes to treat low-back pain Clinical trials regarding radiation countermeasures via bio-manufactured platelets Pediatric lazy-eye detection through retinal imaging Development of flow chemical reactors for atomization of medicinal chemistry process Amount Awarded $200,000 $200,000 $200,000 $200,000 $290,000 $200,000 $145,250 $200,000 Cre8MDI is a Chelmsford based medical device company whose technology is designed to measure arterial stiffness, a proven predictor for cardiovascular disease. Cre8MDI was a Milestone Achievement Program (MAP) awardee in 2015. The MAP grant allowed the company to maintain their pace of development. Cre8MDI is now past the prototype stage, closing in on Phase 1 trials where performance of the system can be validated. Additionally, MLSC funding constituted a third of Cre8MDI s overall funding which reduced its dilution and increased the company s value to investors. 17

STAYING CONNECTED Communication and marketing efforts continued to be a key part of MLSC outreach. The MLSC continued to engage with the life sciences community through the news media, and digitally through the Weekly Digest, social media platforms, and the MLSC website. The MLSC also participated in numerous public and private events around the state and the country to explain the benefits of doing business in Massachusetts. GETTING READY FOR 2018 In anticipation of the return of the BIO International Convention to Boston in 2018, the MLSC and MassBio coordinated on a promotional strategy to help drive interest in the event while in San Diego, which included: A large networking event held at Petco Park attended by Governor Baker Coffee and donuts from Dunkin Donuts within the pavilion A clear unified message supporting the convention in Massachusetts Promotional items with the new Massacshuetts Pavilion Logo & Tagline: Blog of Life Sciences Discourse MLSC President & CEO Travis McCready began his own blog providing insight and views on the life sciences in Massachusetts. Popular posts have covered wearables and human health, female leadership in the life sciences, and the challenges that face the biomanufacturing industry in the Commonwealth. Response from the community has been strong, and with continued activity, the blog will provide an non-traditional view of the industry from a respected source. MLSC Social Media Presence The MLSC continued being an engaging presence on social media, specifically through Twitter. In FY17, the MLSC increased Twitter followers by more than 1,500, and saw an increase in engagement with followers by more than 50%. Traditional Media Newspaper, television and online print remained a focus for traditional communication efforts throughout FY17. Travis continued his monthly appearances on New England Cable News, discussing the latest news in the industry. MLSC coverage in print and online media remained consistent with the Center being covered directly or mentioned in a news item more than 750 times over the course of FY17. 18

ADDITIONAL MLSC FUNDING IN FY17 Throughout the fiscal year, the MLSC - at the discretion of the CEO and with the approval of the Board of Directors - can provide additional funds to new and existing programs or initiatives. In FY17 the MLSC provided six such grants, listed below. Science from Scientists - $50,000 Dearborn Academy/Boston Plan for Excellence - $50,000 Noonan Scholars - $50,000 Boys and Girls Club of Brockton - $50,000 Latino STEM Alliance - $50,000 Lever, Inc - $44,350 A $250,000 grant, outside of the CEO s discretionary grants, was made to the Massachusetts Center for Alzheimer Therapeutics Science (MassCATS) through Massachusetts General Hospital. MassCATS, located at MGH, is a collaboration between the MLSC, MGH, and industry partners, including AbbVie, Biogen, Janssen Pharmaceuticals, Inc., Merck and Sunovion Pharmaceuticals. Total funding for MassCATS totals $1.5 million 19

FINANCIAL SUMMARY The following summarizes the Statement of Net Position and Revenue, Expenses and Changes in Net Position for fiscal years 2017 and 2016 June 30, 2017 June 30, 2016 Assets: Current assets: $ 80,756,645 $ 69,219,571 Assets held on behalf of Neuroscience Consortium $ 1,576,089 $ 773,873 Assets held in escrow - - Noncurrent assets $ 3,848,268 $ 6,483,777 Capital assets $ 42,162 $ 40,234 Total assets $ 86,223,164 $ 76,517,455 Liabilities: Current liabilities $ 46,091,475 $ 30,877,582 Noncurrent liabilities $ 1,576,089 $ 773,873 Total liabilities $ 47,667,564 $ 31,651,455 Net Position: Net investment in capital assets $ 42,162 $ 40,234 Unrestricted $ 38,513,438 $ 44,825,766 Total net position $ 38,555,600 $ 44,866,000 Total liabilities and net position $ 86,223,164 $ 76,517,455 Statements of Revenues, Expenses and Changes in Net Position 20 Revenues and Expenses: Operating revenues $ 52,396,514 $ 54,764,313 Operating expenses (59,004,062) (65,884,705) Operating loss (6,607,548) (11,120,392) Nonoperating revenues $ 297,148 $ 170,495 Capital contributions - $ 10,000,000 (Decrease) increase in net position (6,310,400) (949,897) Net position: Beginning of year $ 44,866,000 $ 45,815,897 End of year $ 38,555,600 $ 44,866,000

THE WAY FORWARD The state budget provides for an FY18 investment fund appropriation of $10 million, contingent on the State Comptroller s declaration of a consolidated net surplus for FY17. The MLSC appreciates, and is grateful to Governor Baker and his Administration, and the entire State Legislature for prioritizing this funding within the state budget. We also thank those who have been integral in establishing the MLSC as the organization it is today and for helping us achieve the success we are known for. It has been encouraging to find that when travelling the state or country for ribbon cuttings, speaking engagements, conferences, or meetings, that the reputation of the Massachusetts life sciences ecosystem precedes us: Our young students in STEM programs are getting - and will continue to have access to - the tools and resources neccesary to become invested and interested in the life sciences. A balanced ecosystem that supports pharmaceuticals, medical device, and additional verticals equally, not found anywhere else in the country. Public and private institutes that individually, could support its own micro-climate, but together creates the densest and arguably, most advanced, population of institutions in the world. The work being done here is second to none, and our job is to make sure everyone who we come in contact with understands that. With the support of the Baker-Polito Administration, the State Legislature, our colleagues in industry and academia, and the stakeholders across the Commonwealth, the Massachusetts Life Sciences Center is setup perfectly to be a key cog supporting this industry and extolling the virtues of maintaining a presence in Massachusetts. We have shed the moniker of an initiative and operate strategically as an agency with the tools necessary to continue making substantial improvements to the life sciences. With all this in place, the Massachusetts Life Sciences Center is excited to help lead the Commonwealth forward as the life sciences industry continues to evolve. 21

1000 Winter Street, Suite 2900 Waltham, MA 02451 P: 781.373.7777 www.masslifesciences.com info@masslifesciences.com